Elisabeth I Minder

Summary

Publications

  1. ncbi Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal
    Elisabeth I Minder
    Stadtspital Triemli, Zentrallabor, Birmensdorferstrasse 497, CH 8063 Zurich, Switzerland
    Health Qual Life Outcomes 8:60. 2010
  2. ncbi Effects of different centrifugation conditions on clinical chemistry and Immunology test results
    Elisabeth I Minder
    Stadtspital Triemli, Central laboratory Birmensdorferstrasse 497 CH 8063 Zürich Switzerland
    BMC Clin Pathol 11:6. 2011
  3. ncbi Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone
    Juergen H Harms
    Stadtspital Triemli, Central Laboratory, University Hospital of Zurich, Zurich, Switzerland
    Photochem Photobiol 85:1434-9. 2009

Collaborators

  • Juergen H Harms
  • Stephan Lautenschlager
  • Christoph E Minder

Detail Information

Publications3

  1. ncbi Patient-recorded outcome to assess therapeutic efficacy in protoporphyria-induced dermal phototoxicity: a proposal
    Elisabeth I Minder
    Stadtspital Triemli, Zentrallabor, Birmensdorferstrasse 497, CH 8063 Zurich, Switzerland
    Health Qual Life Outcomes 8:60. 2010
    ..No standardized tools to quantify the degree of PP-related phototoxicity and its change by medical intervention have been published...
  2. ncbi Effects of different centrifugation conditions on clinical chemistry and Immunology test results
    Elisabeth I Minder
    Stadtspital Triemli, Central laboratory Birmensdorferstrasse 497 CH 8063 Zürich Switzerland
    BMC Clin Pathol 11:6. 2011
    ..abstract:..
  3. ncbi Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone
    Juergen H Harms
    Stadtspital Triemli, Central Laboratory, University Hospital of Zurich, Zurich, Switzerland
    Photochem Photobiol 85:1434-9. 2009
    ..The findings demonstrate beneficial effects of afamelanotide in patients with EPP. Due to the limited number of patients enrolled and the design being an open-label study, confirmation by a large-scale trial is required...